The global Alzheimer's Association round robin study on plasma amyloid β methods
Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring2021Vol. 13(1), pp. e12242–e12242
Citations Over TimeTop 10% of 2021 papers
Josef Pannee, Leslie M. Shaw, Magdalena Korecka, Teresa Waligórska, Charlotte E. Teunissen, Erik Stoops, Hugo Vanderstichele, Kimberley Mauroo, Inge M.W. Verberk, Ashvini Keshavan, Pedro Pesini, Leticia Sarasa, María Pascual‐Lucas, Noelia Fandos, José‐Antonio Allué, Erik Portelius, Ulf Andréasson, Ritsuko Yoda, Akinori Nakamura, Naoki Kaneko, Shieh‐Yueh Yang, Huei‐Chun Liu, Stefan Palme, Tobias Bittner, Kwasi G. Mawuenyega, Vitaliy Ovod, James Bollinger, Randall J. Bateman, Yan Li, Jeffrey L. Dage, Erik Stomrud, Oskar Hansson, Jonathan M. Schott, Kaj Blennow, Henrik Zetterberg
Abstract
The poor correlations for Aβ42 in plasma might have several potential explanations, such as the high levels of plasma proteins (compared to CSF), sensitivity to pre-analytical sample handling and specificity, and cross-reactivity of different antibodies. Different methods might also measure different pools of plasma Aβ42. We, however, hypothesize that greater correlations might be seen in future studies because many of the methods have been refined during completion of this study.
Related Papers
- → Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging.(1994)469 cited
- → Cerebrospinal fluid and plasma distribution of myo-inositol and other polyols in Alzheimer disease(1996)32 cited
- → Cerebrospinal fluid endothelin-1 in Alzheimer's disease and senile dementia of Alzheimer type(1992)20 cited
- → Cortisol Regulation of Gamma-Glutamyl Transpeptidase in Liver, Choroid Plexus, Blood Plasma and Cerebrospinal Fluid of Developing Chick Embryo(1981)10 cited
- → Amyloid- Signal Transduction Antagonist, A Possible Way to Relief Alzheimers Disease(2023)